<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858284</url>
  </required_header>
  <id_info>
    <org_study_id>TUG-US-001</org_study_id>
    <nct_id>NCT02858284</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Masked, 8-week Pilot Study Evaluating the Safety and Efficacy of the TUG (Therapeutic Ultrasound for Glaucoma) Compared to Sham in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyeSonix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyeSonix</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the TUG device is safe and effective in
      patients with primary open angle glaucoma or ocular hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean IOP</measure>
    <time_frame>through subject study completion; average 2 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mean diurnal IOP</measure>
    <time_frame>Week 4 (Visit 5) and Week 8 (Visit 7)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in IOP from baseline</measure>
    <time_frame>through subject study completion; average 2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Glaucoma, Primary Open Angle</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>TUG Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 time external application - device powered on</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>1 time external application - device powered off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TUG</intervention_name>
    <description>Therapeutic Ultrasound for Glaucoma</description>
    <arm_group_label>TUG Device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham</intervention_name>
    <arm_group_label>Sham</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Diagnosis of primary open angle glaucoma or ocular hypertension in both eyes

          -  Be willing to discontinue disallowed products and/or medications during the period
             indicated prior to participation or throughout the study

          -  Be willing to provide written informed consent

          -  Be willing and able to follow instructions

          -  A negative urine pregnancy test and agree to an acceptable form of contraception for
             the duration of the study (if female of childbearing potential)

        Exclusion Criteria:

          -  Any form of glaucoma other than primary open angle glaucoma or ocular hypertension in
             either eye

          -  Prior or anticipated concurrent use of an investigational drug or device

          -  Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a
             positive pregnancy test

          -  Have a condition (ocular or systemic) or a situation which, in the Investigator's
             opinion, may put the subject at increased risk, may confound study data, or may
             interfere significantly with the subject's study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ryan Bouchard</last_name>
    <phone>+1-978-685-8900</phone>
    <phone_ext>9574</phone_ext>
    <email>rbouchard@oraclinical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>North Shore Eye Care</name>
      <address>
        <city>Salem</city>
        <state>Massachusetts</state>
        <zip>01970</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>978-745-0654</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mundorf Eye Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-334-3222</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

